<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36177038</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Case report: Novel treatment regimen for <i>enterovirus</i> encephalitis in SCID.</ArticleTitle><Pagination><StartPage>930031</StartPage><MedlinePgn>930031</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">930031</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.930031</ELocationID><Abstract><AbstractText>Most non-polio <i>enterovirus</i> infections in immunocompetent individuals are acute and self-limiting in nature; however, infection can be severe, chronic and have devastating outcomes in immunocompromised hosts. Therapeutic strategies have predominantly involved supportive care, with the lack of approved antiviral treatments proving challenging for management. We report a case of an 8-month-old child who presented with severe <i>enterovirus</i> encephalitis following gene therapy for X-linked severe combined immunodeficiency (X-SCID) and who demonstrated clinical and microbiological improvement after a novel regimen of favipiravir, fluoxetine, and high-dose intravenous immunoglobulin (IVIg). The patient presented 6 weeks post-gene therapy with rapid neurological deterioration in the context of incomplete immune reconstitution, with microbiological and radiological evidence confirming <i>enterovirus</i> encephalitis. His neurologic examination stabilised 8 weeks after treatment, and he subsequently demonstrated excellent immune recovery. This is the first case report of combined therapy with favipiravir, fluoxetine, and high-dose IVIg in the context of severe <i>enterovirus</i> encephalitis in an immunocompromised host. This case highlights the importance of considering <i>enterovirus</i> encephalitis in immunocompromised patients presenting with both acute and chronic neurological signs, as well as developmental regression. The demonstrated treatment success and the associated low risk of toxicity warrant further investigation of this therapeutic regimen.</AbstractText><CopyrightInformation>Copyright Â© 2022 Chetty, Cheng, Kaliakatsos, Gonzalez-Granado, Klapsa, Martin, Bamford, Breuer and Booth.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chetty</LastName><ForeName>Kritika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Immunology, Great Ormond Street Hospital, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular and Cellular Immunology Section, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Iek</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pharmacy department, Great Ormond Street Hospital for Children National Health Service (NHS) Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Faulty of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaliakatsos</LastName><ForeName>Marios</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Great Ormond Street Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Granado</LastName><ForeName>Luis Ignacio</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Servicio de Pediatria, Hospital Universitario 12 de octubre, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klapsa</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vaccines Division, The Medicines and Healthcare products Regulatory Agency, Potters Bar, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccines Division, The Medicines and Healthcare products Regulatory Agency, Potters Bar, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamford</LastName><ForeName>Alasdair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection, Immunity and Inflammation Teaching and Research Department, Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breuer</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booth</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, Great Ormond Street Hospital, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular and Cellular Immunology Section, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EW5GL2X7E0</RegistryNumber><NameOfSubstance UI="C462182">favipiravir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="Y">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral agents</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">gene therapy (GT)</Keyword><Keyword MajorTopicYN="N">infectious encephalitis</Keyword><Keyword MajorTopicYN="N">primary immunodeficiency diseases</Keyword><Keyword MajorTopicYN="N">severe combined immunodeficiency</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>30</Day><Hour>2</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36177038</ArticleId><ArticleId IdType="pmc">PMC9513597</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.930031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother (2009) 53(10):4501â3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764203</ArticleId><ArticleId IdType="pubmed">19635956</ArticleId></ArticleIdList></Reference><Reference><Citation>Misbah SA, Spickett GP, Ryba PCJ, Hockaday JM, Kroll JS, Sherwood C, et al. . Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol (1992) 12(4):266â70.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, et al. . Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob Agents Chemother (2015) 59(12):7782â5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gofshteyn J, CÃ¡rdenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurolo (2016) 64:94â8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27640319</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res (2013) 100(2):446â54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880838</ArticleId><ArticleId IdType="pubmed">24084488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li G, Yuan S, Gao Q, Lan K, Altmeyer R, et al. . In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob Agents Chemother (2016) 60(9):5357â67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997834</ArticleId><ArticleId IdType="pubmed">27353263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bixler SL, Bocan TM, Wells J, Wetzel KS, van Tongeren SA, Garza NL, et al. . Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antiviral Res (2018) 151:50â4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29289664</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung DT, Ghula S, Aziz JMA, Makram AM, Tawfik GM, Abozaid AAF, et al. . The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis (2022) 120:217â27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023375</ArticleId><ArticleId IdType="pubmed">35470021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan SH, Lai CC, Chang SP, Lu LC, Hung SH, Lin WT. Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol (2022) 15(6):759â66.</Citation><ArticleIdList><ArticleId IdType="pubmed">35579014</ArticleId></ArticleIdList></Reference><Reference><Citation>Madelain V, MentrÃ© F, Baize S, Anglaret X, LaouÃ©nan C, Oestereich L, et al. . Modeling favipiravir antiviral efficacy against emerging viruses: From animal studies to clinical trials. CPT: Pharmacometrics Syst Pharmacol (2020) 9(5):258â71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239338</ArticleId><ArticleId IdType="pubmed">32198838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouazza N, Treluyer JM, Foissac F, MentrÃ© F, Taburet AM, Guedj J, et al. . Favipiravir for children with Ebola. Lancet (2015) 385(9968):603â4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25706078</ArticleId></ArticleIdList></Reference><Reference><Citation>Madelain V, Nguyen THT, Olivo A, de Lamballerie X, Guedj J, Taburet AM, et al. . Ebola Virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinetics. (2016) 55(8):907â23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680399</ArticleId><ArticleId IdType="pubmed">26798032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph H, Schroten H, Tenenbaum T. Enterovirus infections of the central nervous system in children: An update. Pediatr Infect Dis J (2016) 35(5):567â9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26862675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: Update on epidemiology and therapy. J Allergy Clin Immunol: In Practice. (2016) 4(6):1059â65.</Citation><ArticleIdList><ArticleId IdType="pubmed">26883540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffner MA, Sullivan KE, Henrickson SE. Recurrent and sustained viral infections in primary immunodeficiencies. Front Immunol (2017) 8(JUN):665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474473</ArticleId><ArticleId IdType="pubmed">28674531</ArticleId></ArticleIdList></Reference><Reference><Citation>Galama JMD. Enteroviral infections in the immunocompromised host. Rev Res Med Microbiol (1997) 8(1):33â40.</Citation></Reference><Reference><Citation>Chakrabarti S, Osman H, Collingham KE, Fegan CD, Milligan DW. Enterovirus infections following T-cell depleted allogeneic transplants in adults. Bone Marrow Transplant (2004) 33(4):425â30.</Citation><ArticleIdList><ArticleId IdType="pubmed">14688815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>